Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2003

View Archived Issues

Atazanavir-containing regimens in the management of HIV-1 infection

Multibinding beta2-adrenoceptor agonists designed by Theravance researchers

Stimulation of the dopamine D4 receptor enhances novelty-seeking behavior in mice

Glucagon antagonists/inverse agonists in Novo Nordisk pipeline

Pfizer patent covers new bicyclic FTase inhibitors

Pemetrexed in combination with cisplatin significantly extends survival in mesothelioma patients

New AMPA receptor modulators and their use claimed by Servier

GSK scientists prepare and test new cathepsin K inhibitors

Cholesterol management vaccine is a feasible human therapy

New prodrugs of dopamine D1 receptor agonists with utility in Parkinson's disease

Novel NOS inhibitors and their use in neurological disorders reported by Schering AG

Preclinical profile of a novel noncompetitive AMPA receptor antagonist, YM-928

Shire BioChem acquires Canadian rights to five Draxis products

Axcan acquires license to drug for treatment of hepatic encephalopathy

Cell Genesys and Novartis enter oncolytic virus therapy alliance

OPC-6535 enters two pivotal trials in ulcerative colitis

Savient acquires huperzine A marketing rights for U.S. and Europe

Orphan drug status awarded to Transgene's Ad-IFNgamma

Xenova updates R&D reorganization status

Phase III Noxafil study meets primary endpoint

Sweden is the first to approve transplant drug Certican

Anti-gp75 antibodies evaluated as potential therapies for melanoma

Humanized antibodies targeting denatured collagen inhibit angiogenesis and tumor growth

ZK-EPO: a promising new synthetic epothilone tubulin stabilizer

Pharma Mar remains fully confident in the efficacy of Yondelis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...